Shares of Zura Bio Limited (NASDAQ:ZURA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.75.
ZURA has been the topic of a number of analyst reports. Wedbush initiated coverage on Zura Bio in a research note on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective on the stock. Chardan Capital raised their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Wednesday, April 8th. Finally, Oppenheimer decreased their price target on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th.
Read Our Latest Stock Analysis on Zura Bio
Zura Bio Stock Down 2.3%
Zura Bio (NASDAQ:ZURA – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). As a group, equities analysts expect that Zura Bio will post -0.73 EPS for the current fiscal year.
Insider Transactions at Zura Bio
In other Zura Bio news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were purchased at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. This represents a 43.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 14.23% of the company’s stock.
Institutional Trading of Zura Bio
Hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new stake in Zura Bio in the 4th quarter worth about $30,000. Scientech Research LLC acquired a new stake in Zura Bio in the 3rd quarter worth about $45,000. Dimensional Fund Advisors LP acquired a new stake in Zura Bio in the 4th quarter worth about $123,000. Squarepoint Ops LLC purchased a new position in shares of Zura Bio in the 3rd quarter worth about $109,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Zura Bio in the 3rd quarter valued at about $138,000. 61.14% of the stock is owned by institutional investors and hedge funds.
About Zura Bio
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
Read More
- Five stocks we like better than Zura Bio
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
